



Supplemental Fig 1. Effects of VMY. **A)** Cell cycle profile of NIH3T3 cells treated with VMY as shown. **B,C)** determination of ED50 levels for cell death with VMY or Flavo (flavopiridol,) respectively. PVB failed to induce more than 8% cell death at concentrations as high as 60 uM, **D)** Effect of PVB, VMY or Flavo (flavopiridol) on p21CIP1 levels. Western blotting was performed on extracts from DAOY cells Average and standard deviation for $N \geq 3$ separate experiments. **Inset.** A representative western blot showing protein levels of p21CIP1 and β -actin. *, $p \leq 0.05$. In all experiment, cells were treated were for 18 hours.



Supplemental Fig 2. Effect of VMY and flavopiridol on CDK1. DAOY cells were treated with nocodazole for 18 hours. The nocodazole was removed and the cells were treated for 1 hour with the compounds as shown. The levels of tyrosine-15 phosphorylation CDK1 were assessed using an anti phospho-tyrosine-15 CDK1 antibody (Cell Signaling). PVB, VMY and Flavopiridol (Flavo) had no significant effect on levels the inhibitory T-15 phosphorylation site on CDK1. **Inset.** Western blot showing protein levels of pT15-CDK1 and β-actin.



Supplemental Fig 3. Effect of PVB, VMY and flavopiridol on **A)** Aurora Kinase A (Sigma) and **B)** Wee1(Santa Cruz) protein levels. Western blotting was performed on extracts from DAOY cells treated as shown for 1 hour following release from 18 hrs nocodazole block. **Insets.** Western blot showing protein levels of **A)** Aurora Kinase A, **B)** Wee1 and β-actin. Flavo, flavopiridol.